Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
5d
Medpage Today on MSNAdjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerPost-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.
(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study. Efficacy outcomes with belzutifan versus everolimus by ...
1d
GlobalData on MSNSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentSellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results